PMID- 22954755
OWN - NLM
STAT- MEDLINE
DCOM- 20130319
LR  - 20191210
IS  - 1573-2509 (Electronic)
IS  - 0920-9964 (Linking)
VI  - 141
IP  - 2-3
DP  - 2012 Nov
TI  - Effects of omega-3 dietary supplement in prevention of positive, negative and 
      cognitive symptoms: a study in adolescent rats with ketamine-induced model of 
      schizophrenia.
PG  - 162-7
LID - S0920-9964(12)00425-2 [pii]
LID - 10.1016/j.schres.2012.08.002 [doi]
AB  - Omega-3 has shown efficacy to prevent schizophrenia conversion in ultra-high risk 
      population. We evaluated the efficacy of omega-3 in preventing ketamine-induced 
      effects in an animal model of schizophrenia and its effect on brain-derived 
      neurotrophic factor (BDNF). Omega-3 or vehicle was administered in Wistar male 
      rats, both groups at the 30th day of life for 15days. Each group was split in two 
      to receive along the following 7days ketamine or saline. Locomotor and 
      exploratory activities, memory test and social interaction between pairs were 
      evaluated at the 52nd day of life. Prefrontal-cortex, hippocampus and striatum 
      tissues were extracted right after behavioral tasks for mRNA BDNF expression 
      analysis. Bloods for serum BDNF were withdrawn 24h after the end of behavioral 
      tasks. Locomotive was increased in ketamine-treated group compared to control, 
      omega-3 and ketamine plus omega-3 groups. Ketamine group had fewer contacts and 
      interaction compared to other groups. Working memory and short and long-term 
      memories were significantly impaired in ketamine group compared to others. Serum 
      BDNF levels were significantly higher in ketamine plus omega-3 group. There was 
      no difference between groups in prefrontal-cortex, hippocampus and striatum for 
      mRNA BDNF expression. Administration of omega-3 in adolescent rats prevents 
      positive, negative and cognitive symptoms in a ketamine animal model of 
      schizophrenia. Whether these findings are consequence of BDNF increase it is 
      unclear. However, this study gives compelling evidence for larger clinical trials 
      to confirm the use of omega-3 to prevent schizophrenia and for studies to 
      reinforce the beneficial role of omega-3 in brain protection.
CI  - Copyright (c) 2012 Elsevier B.V. All rights reserved.
FAU - Gama, Clarissa S
AU  - Gama CS
AD  - Laboratory of Molecular Psychiatry, INCT for Translational Medicine, Hospital de 
      Clinicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto 
      Alegre, Brazil. clarissasgama@gmail.com
FAU - Canever, Lara
AU  - Canever L
FAU - Panizzutti, Bruna
AU  - Panizzutti B
FAU - Gubert, Carolina
AU  - Gubert C
FAU - Stertz, Laura
AU  - Stertz L
FAU - Massuda, Raffael
AU  - Massuda R
FAU - Pedrini, Mariana
AU  - Pedrini M
FAU - de Lucena, David F
AU  - de Lucena DF
FAU - Luca, Renata D
AU  - Luca RD
FAU - Fraga, Daiane B
AU  - Fraga DB
FAU - Heylmann, Alexandra S
AU  - Heylmann AS
FAU - Deroza, Pedro F
AU  - Deroza PF
FAU - Zugno, Alexandra I
AU  - Zugno AI
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120904
PL  - Netherlands
TA  - Schizophr Res
JT  - Schizophrenia research
JID - 8804207
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Excitatory Amino Acid Antagonists)
RN  - 0 (Fatty Acids, Omega-3)
RN  - 0 (RNA, Messenger)
RN  - 690G0D6V8H (Ketamine)
SB  - IM
MH  - Analysis of Variance
MH  - Animals
MH  - Avoidance Learning/drug effects/physiology
MH  - Brain/metabolism/pathology
MH  - Brain-Derived Neurotrophic Factor/genetics/metabolism
MH  - Cognition Disorders/*prevention & control
MH  - *Dietary Supplements
MH  - Disease Models, Animal
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Excitatory Amino Acid Antagonists/toxicity
MH  - Fatty Acids, Omega-3/*administration & dosage
MH  - Humans
MH  - Inhibition, Psychological
MH  - Interpersonal Relations
MH  - Ketamine/toxicity
MH  - Male
MH  - Motor Activity/drug effects/physiology
MH  - RNA, Messenger/metabolism
MH  - Rats
MH  - Rats, Wistar
MH  - Schizophrenia/chemically induced/*complications/*diet therapy
MH  - Time Factors
EDAT- 2012/09/08 06:00
MHDA- 2013/03/21 06:00
CRDT- 2012/09/08 06:00
PHST- 2012/06/04 00:00 [received]
PHST- 2012/07/31 00:00 [revised]
PHST- 2012/08/02 00:00 [accepted]
PHST- 2012/09/08 06:00 [entrez]
PHST- 2012/09/08 06:00 [pubmed]
PHST- 2013/03/21 06:00 [medline]
AID - S0920-9964(12)00425-2 [pii]
AID - 10.1016/j.schres.2012.08.002 [doi]
PST - ppublish
SO  - Schizophr Res. 2012 Nov;141(2-3):162-7. doi: 10.1016/j.schres.2012.08.002. Epub 
      2012 Sep 4.